Drug
nivolumab and hyaluronidase-nvhy
Marketed as OPDIVO QVANTIG.
Generic name
nivolumab and hyaluronidase-nvhy
Brand names
OPDIVO QVANTIG
First FDA approval
2024-12-27
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761381 | OPDIVO QVANTIG | 2024-12-27 | BRISTOL-MYERS SQUIBB |
Manufacturers
BRISTOL-MYERS SQUIBB
Frequently asked questions
When was nivolumab and hyaluronidase-nvhy FDA approved?
Earliest FDA approval on record: 2024-12-27.
What brand names are sold as nivolumab and hyaluronidase-nvhy?
OPDIVO QVANTIG.
Sources
Appeal a nivolumab and hyaluronidase-nvhy denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com